GRAYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 3月 2023 @ 05:00):

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve...

Stats
本日の出来高	24 628.00
平均出来高	5 277.00
時価総額	120.98M
EPS	$0 ( 2024-03-06 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.267
ATR14	$0.618 (22.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	Wilson Robert N	Buy	506	Common Stock
2023-11-07	Leheny A. Rachel	Buy	2 000	Common Stock
2023-11-06	Roberts Eric W	Buy	2 400	Common Stock
2023-11-03	Roberts Eric W	Buy	11 249	Common Stock
2023-11-03	Roberts Eric W	Buy	3 700	Common Stock

INSIDER POWER
96.28
Last 97 transactions
Buy: 3 103 303 \| Sell: 60 672

ボリューム相関

長: -0.13 (neutral)

短: 0.37 (neutral)

Signal:(40.58) Neutral

Graybug Vision, Inc. 相関

10 最も正の相関
INFI	0.939
POWW	0.935
VSTA	0.931
TTCF	0.926
NOTV	0.925
JWEL	0.924
ACET	0.918
COMT	0.917
TCDA	0.915
VCSA	0.91

10 最も負の相関
IMMR	-0.919
CCRC	-0.918
IBEX	-0.899
PBFS	-0.89
MGI	-0.883
ISIG	-0.878
ACLX	-0.875
SEDG	-0.873
MSON	-0.866
ARNA	-0.851

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Graybug Vision, Inc. 相関 - 通貨/商品

-0.11
( neutral )

0.45
( neutral )

0.46
( neutral )

0.00
( neutral )

-0.18
( neutral )

0.14
( neutral )

Graybug Vision, Inc. 財務諸表

Annual	2022
収益:	$2.96M
総利益:	$2.96M (100.00 %)
EPS:	$-319.50

FY	2022
収益:	$2.96M
総利益:	$2.96M (100.00 %)
EPS:	$-319.50

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.690

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5.25

Financial Reports:

No articles found.

Graybug Vision, Inc.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.